Navigation Links
Neurocrine Biosciences Reports Third Quarter 2008 Results
Date:10/28/2008

ces with respect to the Company's clinical programs include, but are not limited to, risk that the Company's elagolix Phase II clinical trials will fail to demonstrate that elagolix is safe and effective; risk that preclinical data will indicate that urocortin 2 is not suitable for further clinical studies; risk that the CRF1 receptor antagonist candidate's Phase II proof of concept clinical studies will not support further clinical studies; and overall risk that the Company's clinical candidates will not proceed to later stage clinical trials. Risks associated with the Company's indiplon program include, but are not limited to, risk that indiplon approval and subsequent commercialization may be indefinitely delayed or never accomplished. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial manufacturing and marketing and sales activities; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and the other risks described in the Company's report on Form 10-K for the year ended December 31, 2007 and report on Form 10Q for the quarter ended June 30, 2008. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.

NEUROCRINE BIOSCIENCES, INC.

Condensed Consolidated Statements of Operations

(in thousands, except for per share data)

Three Months Ended Nine Months Ended

September 30,
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Webcast Alert: Neurocrine Announces 3Q 08 Financial Results
2. Neurocrine Biosciences to Present at the Oppenheimer 19th Annual Healthcare Conference
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results
4. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
5. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
6. Neurocrine Biosciences Reports Second Quarter 2008 Results
7. Neurocrine Biosciences Announces Conference Call and Webcast To Present Second Quarter 2008 Financial Results
8. Neurocrine Biosciences to Present at the 2008 Citi Investment Research Global Health Care Conference
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results
10. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results
11. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... At the request of the AMA, the Federal ... the public comment period (Docket No. FAA-2014-0396) for FAA’s ... by Congress as part of the FAA Modernization and ... new deadline for comments as September 23, 2014. , ... in the Federal Register on July 25, 2014, the ...
(Date:7/24/2014)... Tenn., July 24, 2014 -- A novel combination of ... Department of Energy,s Oak Ridge National Laboratory an unprecedented ... its unusual physical and electrochemical properties. , The ... oxygen affects the surface of a perovskite manganite, a ... The new avenue to understand surface behavior could benefit ...
(Date:7/24/2014)... July 24, 2014  Asterias Biotherapeutics, Inc. (OTCBB: ... field of regenerative medicine, announced today that it ... to investors on Tuesday, July 29, 2014, at ... will include an overview of Asterias, business strategy ... visit http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 minutes ...
(Date:7/24/2014)... leader Yung-Eun Sung has announced that they have ... graphenes which can be applied as high performance ... Sung is both a group leader at the ... Science* (IBS) and a professor at the Seoul ... with regards to the development of relative simplicity, ...
Breaking Biology Technology:FAA Grants Comment Extension at the Request of AMA 2ORNL study reveals new characteristics of complex oxide surfaces 2Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
... , THOROLD, ON , ... innovative privately held Canadian biotechnology company focusing primarily on ... purification, today announced the launch of 10 new kits ... from blood, plasma and serum, including circulating nucleic acids. ...
... , Collaboration will further evaluate novel stem cell-derived ... genes relevant to disease progression , CAMBRIDGE, Mass. ... California Stem Cell, Inc. (CSC) and ALS Therapy Development ... expansion of their collaboration aimed at advancing a potential stem ...
... SANTA ROSA, Calif. , Feb. 2 Just in ... introduces the newest in their scientifically formulated product line: CIRCUTOL™ Cardiovascular ... in 1995 by integrative medicine pioneer, Dr. Isaac Eliaz ... being at the forefront of the latest developments in natural alternative health ...
Cached Biology Technology:Norgen Biotek Launches 10 New Kits for the Isolation of High-Quality Circulating Nucleic Acids from Blood, Plasma and Serum 2California Stem Cell and ALS Therapy Development Institute Extend Their Collaboration to Advance Potential Stem Cell Assisted Therapy for ALS 2California Stem Cell and ALS Therapy Development Institute Extend Their Collaboration to Advance Potential Stem Cell Assisted Therapy for ALS 3California Stem Cell and ALS Therapy Development Institute Extend Their Collaboration to Advance Potential Stem Cell Assisted Therapy for ALS 4Just in Time for Heart Health Month... TRIPLE Cardiovascular Health Support From EcoNugenics 2Just in Time for Heart Health Month... TRIPLE Cardiovascular Health Support From EcoNugenics 3
(Date:7/24/2014)... Scientists at The New York Stem Cell ... to creating a viable cell replacement therapy for ... , For the first time, NYSCF scientists generated ... samples of patients with primary progressive multiple sclerosis ... induce these stem cells into becoming oligodendrocytes, the ...
(Date:7/24/2014)... 24, 2014) Scientists at The New York ... step closer to creating a viable cell replacement ... cells. , For the first time, NYSCF ... from skin samples of patients with primary progressive ... protocol to induce these stem cells into becoming ...
(Date:7/24/2014)... identified two factors that characterize sustainable university and ... highly qualified physics teachers. Specifically, one or more ... education in combination with institutional motivation and commitment ... Technology, Engineering and Math (STEM) teacher shortages are ... the way for institutions seeking to increase the ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Creating sustainable STEM teacher preparation programs 2
... 25, 2010 - A first-of-its-kind study of a Caspian ... current harvest rates are four to five times higher ... results, which will be published in an upcoming issue ... conservation strategies for beluga sturgeon should focus on reducing ...
... A study involving the world,s deadliest substance has yielded a ... to more efficient strategies against toxins that may be used ... stings, and even some important chronic diseases. A ... agents that seek out Botulinum toxin molecules and bind to ...
... as they evolved over hundreds of generations to infect bacteria. ... the viruses evolved at a quicker rate and generated greater ... adapt to the viral infection. The study shows, for ... Valen was correct in his ,Red Queen Hypothesis,. The ...
Cached Biology News:New research shows fishery management practices for beluga sturgeon must change 2New research shows fishery management practices for beluga sturgeon must change 3Novel antitoxin strategy developed using 'tagged binding agents' 2Novel antitoxin strategy developed using 'tagged binding agents' 3Scientists reveal driving force behind evolution 2
... to the maintenance of appropriate levels ... important and diverse as those involved ... stress response, antigen presentation, modulation of ... cell cycle regulation, transcription, and signalling ...
... Proteolytic degradation is critical to the ... and regulatory proteins as important and ... metabolism, heat shock and stress response, ... receptors and ion channels, cell cycle ...
... Optics LIBS2000+ Spectrometers (sold separately) in the ... Chamber to offer numerous configuration options and ... include a high-power 1064 nm Nd:YAG laser, ... sample positioning, laser spot diameter control from ...
... Picking,A modified digital scanner serves as the ... the five standard rack positions on the ... micro well plates on the remaining two ... single spots by mouse-click on the scanned ...
Biology Products: